Impact BioMedical, INC. (IBO)

Import this data to Google Sheets with:

=jivedata("IBO","financials")

Full statements spill as a table. For one cell: =jivedata("IBO","Revenue") or =jivedata("IBO","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.

Impact BioMedical, INC.

IBO • CIK 0001834105

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Revenue from Contract with Customer, Excluding Assessed Tax	$50	—	$32	$35
Operating Income (Loss)	$-4,028	$-28,753	$-4,282	$-5,107
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	$-4,407	$-24,737	$-14,450	$-1,802
Income Tax Expense (Benefit)	$-621	$33	$-2,580	$-2,580
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	—	$-24,770	$-11,870	$778
Net Income (Loss) Attributable to Noncontrolling Interest	—	$-62	$-32	$-13
Net Income (Loss) Attributable to Parent	$-4,407	$-24,708	$-11,838	$791
Cost of Goods and Services Sold	—	—	$424	$424
Selling, General and Administrative Expense	$315	$718	$873	$2,164
Selling and Marketing Expense	—	$633	$24	$5
Professional Fees	$1,262	$446	$1,005	$721
Research and Development Expense	$1,147	$278	$340	$285
Depreciation, Depletion and Amortization, Nonproduction	$1,120	$1,119	$1,145	$1,143
Goodwill, Impairment Loss	$0	$25,093	$25,093	$25,093
Impairment of Long-Lived Assets to be Disposed of	—	$263	$263	$263
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property	—	—	$-12	$-12
Other Expenses	—	$171	$417	$325
Operating Costs and Expenses	—	—	$4,314	$5,142
Interest Income (Expense), Nonoperating, Net	—	$13	$13	$13
Interest Expense	$444	$1,065	$793	$793
Weighted Average Number of Shares Outstanding, Basic	60,248,078	10,757,147	31,550,457	127,229,862

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Cash and Cash Equivalents, at Carrying Value	$1	$1,999	$3	$20
Accounts Receivable, after Allowance for Credit Loss, Current	—	—	$5	$5
Property, Plant and Equipment, Net	$287	$17	$17	$13
Inventory, Net	—	—	$63	$62
Financing Receivable, after Allowance for Credit Loss, Noncurrent	$190	$17	$17	$17
Financing Receivable, after Allowance for Credit Loss, Current	$203	$184	$198	$197
Other Intangible Assets, Net	$18,921	$17,808	$16,994	$16,425
Prepaid Expense and Other Assets, Current	$104	$265	$142	$51
Assets	$44,633	$20,290	$17,405	$16,745
Assets, Current	$332	$2,448	$411	$320
Deferred Income Tax Liabilities, Net	$3,235	$3,268	$688	$688
Liabilities	$16,371	$13,053	$1,850	$2,733
Accounts Payable, Current	$832	$713	$347	$467
Accrued Liabilities, Current	$230	$194	$194	$248
Other Liabilities, Current	—	—	$621	$1,330
Notes Payable, Current	$12,074	$8,878	$8,878	$22,881
Liabilities, Current	$13,136	$9,785	$1,162	$2,045
Preferred Stock, Value, Issued	$60	$60	$60	$60
Common Stock, Value, Issued	$10	$11	$105	$108
Additional Paid in Capital	—	$41,857	$62,011	$63,150
Retained Earnings (Accumulated Deficit)	$-12,961	$-37,669	$-49,507	$-52,492
Stockholders' Equity Attributable to Parent	$25,222	$4,259	$12,609	$10,766
Stockholders' Equity Attributable to Noncontrolling Interest	$3,040	$2,978	$2,946	$3,246
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	$28,262	$7,237	$15,555	$14,012
Preferred Stock, Shares Authorized	100,000,000	100,000,000	100,000,000	100,000,000
Preferred Stock, Shares Issued	60,496,041	60,496,041	0	0
Preferred Stock, Liquidation Preference, Value	$60	$60	$0	$0
Common Stock, Shares Authorized	4,000,000,000	4,000,000,000	4,000,000,000	4,000,000,000
Common Stock, Shares, Issued	10,000,000	11,503,955	104,621,231	107,821,231

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	—	$-24,770	$-11,870	$778
Net Cash Provided by (Used in) Operating Activities	$-2,851	$-3,919	$-1,890	$-508
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	$-1	$1,998	$-1,996	$-614
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations	$1	$1,999	$3	$-1,295
Depreciation, Depletion and Amortization	$1,120	$1,119	$1,145	$1,143
Proceeds from Sale of Notes Receivable	—	$2	$3	$3
Share-based Payment Arrangement, Noncash Expense	—	$19	$13	$1,449
Net Cash Provided by (Used in) Investing Activities	$-15	$2	$3	$3
Issuance of Stock and Warrants for Services or Claims	—	—	$190	$190
Deferred Income Tax Expense (Benefit)	$-621	$33	$-2,580	$-2,580
Gain (Loss) on Disposition of Intangible Assets	—	—	$-12	$-12
Impairment of Long-Lived Assets to be Disposed of	—	$263	$263	$263
Goodwill, Impairment Loss	$0	$25,093	$25,093	$25,093
Proceeds from Related Party Debt	$2,865	—	$184	$184
Repayments of Related Party Debt	—	—	$293	$293
Proceeds from Issuance of Long-term Debt	—	—	$1,124	$1,124
Proceeds from Issuance of Common Stock	—	$3,726	$3,726	$3,726
Net Cash Provided by (Used in) Financing Activities	$2,865	$5,915	$-109	$-109
Increase (Decrease) in Accounts Receivable	—	—	$1	$0
Increase (Decrease) in Inventories	—	—	$-7	$-5
Increase (Decrease) in Prepaid Expense and Other Assets	$-104	$265	$-126	$-119
Increase (Decrease) in Accounts Payable	$293	$-436	$470	$749
Increase (Decrease) in Accrued Liabilities	$167	$-35	$-2	$-19

Loading financial statements…

Import this data to Google Sheets with:

=jivedata("IBO","financials")

Full statements spill as a table. For one cell: =jivedata("IBO","Revenue") or =jivedata("IBO","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.